1. 研究室概要
2. 主要研究テーマ
3. スタッフ
4. 主な研究実績
5. 主な研究費取得状況

当教室は2011年11月に設置された本学臨床医学系でもっとも新しい講座です。主にヒトを対象とした糖尿病合併症、特に糖尿病大血管障害の発症機序とその予防に関する研究、糖尿病性神経障害の病態・病期とそれに基づく治療法の研究に力を入れています。ヒト血管内皮機能を指標として血糖変動や低血糖との関連、血小板機能との関連、食事（栄養素、食物繊維）との関連を研究しています。また、糖尿病の早期から傷害される小径神経線維に着目し、表皮内神経線維密度と痛みや自律神経機能との関連を検討しています。

研究室概要

分野サイト

連絡先

主要研究テーマ

スタッフ

特例准教授（総合臨床研修センター）

研究者総覧 リポジトリ

准教授

研究者総覧 リポジトリ

特任講師

研究者総覧 リポジトリ

助教

研究者総覧 リポジトリ

特任助教

研究者総覧 リポジトリ

主な研究実績

出口尚寿

1. Sugimoto K, Murakami H, Deguchi T, Arimura A, Daimon M, Suzuki S, Shimbo T, Yagihashi S.
   Cutaneous microangiopathy in patients with type 2 diabetes: Impaired vascular endothelial growth factor expression and its correlation with neuropathy, retinopathy and nephropathy.
   J Diabetes Investig 10:1318-1331,2019
2. Masuda T, Ueda M, Suenaga G, Misumi Y, Tasaki M, Izaki A, Yanagisawa Y, Inoue Y, Motokawa H, Matsumoto S, Mizukami M, Arimura A, Deguchi T, Nishio Y, Yamashita T, Inomata Y, Obayashi K, Ando Y.
   Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy.　Neurology　88（23）：2192-2197,2017
3. Horinouchi S, Deguchi T, Arimura K, Arimura A, Dochi Y, Uto T, Nakamura T, Arimura Y, Nishio Y, Takashima H. Median neuropathy at the wrist as an early manifestation of diabetic neuropathy. J Diabetes Invest 5: 709-713, 2014
4. Deguchi T, Nishio Y, Takashima H. Diabetes mellitus and autoimmune neuropathy. Brain Nerve 66(2):135-47, 2014
5. Deguchi T, Rosales R, Hashiguchi T, Arimura K. Antiplatelet Therapy, Diabetic Neuropathy and Peripheral Vascular Disease: A Unitary Approach. J Diabetes Metab S5: 005, 2012
6. Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K, Makisumi K, Arimura K. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabetic Med 26(3): 247-252, 2009
7. Kimura K, Hashiguchi T, Deguchi T, Horinouchi S, Uto T, Oku H, Setoyama S, Maruyama I, Osame M, Arimura K.　Serum VEGF－As a prognostic factor of atherosclerosis. Atherosclerosis 194(1): 182-188, 2007

森野勝太郎

1. Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi     T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H; SUMS-ADDIT-2 Research group. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese    patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial  Diabetes Res Clin Pract. 186: 109781, 2022
2. Iwasaki H, Ichihara Y, Morino K, Lemecha M, Sugawara L, Sawano T, Miake J, Sakurai H, Nishi E, Maegawa H, Imamura T. Takeshi MicroRNA-494-3p inhibits formation of fast oxidative muscle fibres by targeting E1A-binding protein p300 in human-induced pluripotent stem cells. Sci Rep. 11: 1161, 2021
3. Harada K, Morino K (equally contributed), Ishikawa M, Miyazawa I, Yasuda T, Hayashi M, Ishikado A, Maegawa H. Glycemic control and number of natural teeth: analysis of cross-sectional Japanese employment-based dental insurance claims and medical check-up data Diabetol Int. 13: 244-252, 2021
4. Morino K, Kondo K, Tanaka S, Nishida Y, Nakae S, Yamada Y, Ugi S, Fuse K, Miyazawa I, Ohi A, Nishida K, Kurihara M, Sasaki M, Ebine N, Sasaki S, Katsukawa F, Maegawa H. Total energy expenditure is comparable between patients with and without diabetes mellitus: Clinical Evaluation of Energy Requirements in Patients with Diabetes Mellitus (CLEVER-DM) Study. BMJ Open Diabetes Research and Care, 7: e000648, 2019
5. Okamoto T, Morino K, Ugi S, Nakagawa F, Lemecha M, Ida S, Ohashi N, Sato D, Fujita Y, Maegawa H. Microbiome potentiates endurance exercise through intestinal acetate production. Am J Physiol Endocrinol Metab. 16: E956-E966, 2019
6. Inoue H, Morino K, Ugi S, Tanaka-Mizuno S, Fuse K, Miyazawa I, Kondo K, Sato D, Ohashi N, Ida S, Sekine O, Yoshimura M, Murata K, Miura K, Arima H, Maegawa H; SUMS-ADDIT-1 Research group. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. J Diabetes Investig. 10: 1012-1021, 2019
7. Lemecha M, Morino K, Imamura T, Iwasaki H, Ohashi N, Ida S, Sato D, Sekine O, Ugi S, Maegawa H. MiR-494-3p regulates mitochondrial biogenesis and thermogenesis through PGC1-α signalling in beige adipocytes. Sci Rep. 8: 15096, 2018.
8. Kobayashi S,Morino K,Okamoto T,Tanaka M,Ida S,Ohashi N,Murata K,Yanagimachi T,Sakai J,Maegawa H,Fujita Y,Kume S. Acetate derived from the intestinal tract has a critical role in maintaining skeletal muscle mass and strength in mice. Physiol Rep.12:e16047,2024
9. Ohgaku S,Ida S,Ohashi N,Morino K,Ishikado A,Yanagimachi T,Murata K,Sato D,Ugi S,Nasiri A,Shulman Gl,Maegawa H,Kume S,Fujita Y. O-GlcNAc modification in endothelial cells modulates adiposity nia fat absorption from the intestine in mice. Heliyon. 10:e34490,2024 

有村愛子

1. Arimura A, Deguchi T, Sugimoto K, Uto T, Nakamura T, Arimura Y, Arimura K, Yagihashi S, Nishio Y, Takashima H. Intraepidermal nerve fiber density and nerve conduction study parameters correlate with clinical staging of diabetic polyneuropathy.Diabetes Res Clin Pract 99(1): 24-29, 2013

主な研究費取得状況

出口尚寿

森野勝太郎

分野サイト